name: Dravet_syndrome
description: Dravet syndrome is a severe developmental and epileptic encephalopathy
  characterized by treatment-resistant seizures beginning in infancy, developmental
  regression, and cognitive impairment. It is primarily caused by de novo loss-of-function
  mutations in SCN1A, encoding the Nav1.1 voltage-gated sodium channel.
category: Genetic
parents:
- Epileptic Encephalopathy
- Neurologic Disorder
prevalence:
- population: Global
  percentage: Rare
progression:
- phase: Onset
  age_range: Infancy
pathophysiology:
- name: SCN1A Gene Mutation
  description: Heterozygous loss-of-function mutations in SCN1A cause reduced Nav1.1
    sodium channel function, primarily affecting GABAergic inhibitory interneurons.
  evidence:
  - reference: PMID:21463282
    supports: SUPPORT
    snippet: Loss-of-function in Na(v) 1.1 channels results in severely impaired sodium
      current and action potential firing in hippocampal Î³-aminobutyric acid (GABA)ergic
      interneurons without detectable changes in excitatory pyramidal neurons.
- name: Neuronal Hyperexcitability
  description: Reduced inhibitory interneuron function leads to excitatory-inhibitory
    imbalance and network hyperexcitability.
  evidence:
  - reference: PMID:21463282
    supports: SUPPORT
    snippet: The resulting imbalance between excitation and inhibition likely contributes
      to hyperexcitability and seizures.
phenotypes:
- category: Neurologic
  name: Seizures
  description: Treatment-resistant seizures beginning in the first year of life,
    often triggered by fever, with progression to multiple seizure types.
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Include prolonged febrile seizures and various types of epilepsy as the condition
    progresses.
  evidence:
  - reference: PMID:21463282
    supports: SUPPORT
    snippet: a devastating infantile-onset epilepsy with ataxia, cognitive dysfunction,
      and febrile and afebrile seizures resistant to current medications.
  phenotype_term:
    preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
- category: Developmental
  name: Developmental Delay
  description: Progressive developmental regression typically beginning after seizure
    onset, affecting motor, language, and social skills.
  frequency: FREQUENT
  notes: Delays may be observed in motor, language, and social skills.
  evidence:
  - reference: PMID:21463282
    supports: SUPPORT
    snippet: a devastating infantile-onset epilepsy with ataxia, cognitive dysfunction,
      and febrile and afebrile seizures resistant to current medications.
  phenotype_term:
    preferred_term: Developmental Delay
    term:
      id: HP:0001263
      label: Global developmental delay
- category: Cognitive
  name: Intellectual Disability
  description: Cognitive impairment ranging from mild to severe, often progressive
    in nature.
  frequency: FREQUENT
  notes: Ranges from mild to severe.
  phenotype_term:
    preferred_term: Intellectual Disability
    term:
      id: HP:0001249
      label: Intellectual disability
- category: Behavioral
  name: Hyperactivity
  description: Behavioral difficulties including hyperactivity and attention deficits.
  frequency: OCCASIONAL
  notes: Often presents alongside behavioral difficulties.
  phenotype_term:
    preferred_term: Hyperactivity
    term:
      id: HP:0000752
      label: Hyperactivity
genetic:
- name: SCN1A
  association: Pathogenic Mutations
  presence: Positive
  notes: De novo loss-of-function mutations found in approximately 80% of
    Dravet syndrome patients.
  evidence:
  - reference: PMID:21463282
    supports: SUPPORT
    snippet: Complete loss of function in the Na(v) 1.1 channel encoded by the SCN1A
      gene is associated with severe myoclonic epilepsy in infancy (SMEI)
diagnosis:
- name: Genetic Testing for SCN1A Mutations
  presence: Positive in affected individuals
treatments:
- name: Antiepileptic Medications
  description: Includes clobazam, stiripentol, and valproate as first-line agents.
    Sodium channel blockers should be avoided as they may worsen seizures.
  notes: Standard treatment includes clobazam, stiripentol, and valproate.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Ketogenic Diet
  description: High-fat, low-carbohydrate diet that can provide significant seizure
    reduction in some patients.
  notes: Has shown efficacy in reducing seizure frequency in Dravet syndrome patients.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
- name: Supportive Therapies
  description: Therapies such as physical, occupational, and speech therapy to address
    developmental delays and cognitive impairment.
  notes: Comprehensive care includes developmental support and therapeutic interventions.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
- name: Vagus Nerve Stimulation (VNS)
  description: Implanted device that may help reduce seizure frequency in drug-resistant
    cases.
  notes: May be considered for patients with drug-resistant seizures.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
environmental:
- name: Fever
  effect: Triggers Seizures
  notes: Management of fever is crucial to minimize seizure risk.
- name: Excessive Heat and Overexertion
  effect: Exacerbates Symptoms
  notes: Can trigger or worsen seizures.
notes: Early diagnosis and a comprehensive treatment plan are essential to managing
  Dravet syndrome and improving quality of life.
disease_term:
  preferred_term: Dravet syndrome
  term:
    id: MONDO:0100135
    label: Dravet syndrome
